Tag: OCRI
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics
ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer
